STOCK TITAN

LadRx Highlights Patent Issued for Its LADR Technology

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

LadRx Corporation (OTCQB: LADX) has been granted a patent by the USPTO for its maytansinoid-based drug delivery systems. This innovation aims to enhance the delivery of chemotherapeutic agents, allowing for nearly 10 times the dosing of traditional methods. The company's lead drug candidate, Aldoxorubicin, is out-licensed to Immunity Bio, Inc., currently undergoing clinical trials for pancreatic cancer. LadRx's next-generation drugs, LADR7-10, are poised to enter IND-enabling activities and could be ready for Phase 1 trials within 18 months. The patent solidifies LadRx's IP portfolio, supporting its cancer treatment initiatives.

Positive
  • Patent issued for maytansinoid-based drug delivery systems, enhancing IP portfolio.
  • Potential for LADR-based drug candidates to deliver higher doses with reduced side effects.
  • LADR7-10 candidates have shown strong anti-cancer activity and acceptable toxicity in pre-clinical trials.
  • IND-ready candidates could advance to Phase 1 clinical trials in as little as 18 months.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.

Stephen Snowdy, PhD, the Company’s Chief Executive Officer stated:

“Our LADR-based drug candidates are designed to offer higher dosing of chemotherapeutic agents with lower side effects by targeting the chemotherapeutic agent to the tumor environment. Our maytansinoid drugs certainly meet that intent, with LADR-based maytansine being deliverable in animals at nearly 10-times the dosing of non-LADR maytansine. This latest patent adds to the comprehensive portfolio of intellectual property that protects our LADR-based drugs.”

Next-generation Cancer Drugs Based on LADR (“Linker Activated Drug Release”)

Our first-generation LADR-based drug candidate, Aldoxorubicin, has been out-licensed to Immunity Bio, Inc. and is in clinical trials for pancreatic cancer. Our next-generation LADR-based drug candidates employ an improved linker and highly potent chemotherapeutic agents. The Company’s pre-clinical drug candidates are based on this next-gen LADR design, namely LADR7-10. LADR7 and 8 employ the highly potent chemotoxin Auristatin E, while LADR9 and 10 employ another highly potent chemotoxin called Maytansine. LADR7-10 have demonstrated powerful anti-cancer activity in pre-clinical animal models in several different types of solid tumors, and have shown acceptable toxicity profiles. These compounds are positioned to move into IND-enabling activities, and could be IND-ready and into Phase 1 clinical trials in as little as 18 months from funding of the LADR program.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading “Risk Factors”, and current reports filed since the date of the LadRx’s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

About LadRx

LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC). LadRx Corporation’s website is www.ladrxcorp.com.

Longacre Square Partners

Greg Marose / Charlotte Kiaie

ladrx@longacresquare.com

Source: LadRx Corporation

FAQ

What is the significance of the patent issued to LadRx Corporation?

The patent enhances LadRx's intellectual property portfolio for maytansinoid-based drug delivery systems, crucial for its cancer therapeutics.

What are the main drug candidates being developed by LadRx Corporation?

LadRx is developing LADR7-10, next-generation drugs with strong anti-cancer activity, with the potential to enter clinical trials soon.

How does LadRx's drug delivery system improve cancer treatment?

The LADR-based system allows for higher dosing of chemotherapy agents while minimizing side effects by targeting the tumor environment.

What progress has been made on Aldoxorubicin?

Aldoxorubicin is currently in clinical trials for pancreatic cancer after being out-licensed to Immunity Bio, Inc.

When can we expect LadRx's next-generation drugs to enter clinical trials?

LADR7-10 candidates could be ready for Phase 1 clinical trials within 18 months, pending funding.

LADRX CORPORATION

OTC:LADX

LADX Rankings

LADX Latest News

LADX Stock Data

445.58k
489.20k
1.19%
0.75%
Biotechnology
Healthcare
Link
United States of America
Los Angeles